查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1671994

全球尿路上皮癌診斷市場：產業分析、規模、佔有率、成長、趨勢和預測（2025-2032 年）

Urothelial Carcinoma Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 191 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

預計 2025 年全球尿路上皮癌診斷市場規模將達到 18.448 億美元，到 2032 年將達到 38.313 億美元，預測期內（2025-2032 年）的複合年成長率為 10.9%。

尿路上皮癌，通常稱為膀胱癌，是一種惡性腫瘤，需要早期準確診斷才能有效治療並改善患者預後。尿路上皮癌診斷市場包括各種診斷方式，例如尿液細胞學、生物標記測試、螢光雜合反應(FISH)、膀胱鏡檢查和影像技術。這些診斷方法在疾病檢測、分期和復發監測中發揮重要作用。市場成長的動力包括診斷技術的進步、膀胱癌發病率的增加、非侵入性診斷方法的日益普及、患者的便利性和早期發現率的提高。

全球尿路上皮癌診斷市場受到幾個關鍵因素的推動，包括膀胱癌盛行率的上升，尤其是在老化人口和吸菸、接觸工業化學物質等高風險因素的人群中。此外，人們對尿液生物標記檢測等非侵入性、微創診斷方法的日益偏好也促進了市場的擴張。此外，分子診斷和人工智慧成像解決方案的技術進步正在提高診斷的準確性和效率。液態切片和次世代定序(NGS) 的日益融合也透過為尿路上皮癌患者提供準確和個性化的診斷見解進一步推動了市場成長。

由於人工智慧和機器學習在診斷影像中的應用越來越多、精準醫療方法的不斷擴大以及對早期癌症檢測計劃的日益關注，尿路上皮癌診斷市場提供了巨大的成長機會。數位病理學和人工智慧輔助診斷平台的進步將提高診斷效率，減少假陽性或假陰性的機會，並改善患者的治療效果。此外，開發具有成本效益、快速的照護現場上皮癌即時診斷解決方案可能會促進服務不足地區的市場發展。診斷公司和研究機構之間為推進生物標記的發現和檢驗建立的合作夥伴關係也為這個發展中市場提供了豐厚的成長前景。

本報告研究了全球尿路上皮癌診斷市場，提供了對產品、測試、最終用戶和地區的趨勢以及參與市場的公司概況的見解。

目錄

第1章執行摘要

第2章 市場概況

  • 市場範圍和定義
  • 市場動態
  • 宏觀經濟因素
  • COVID-19影響分析
  • 預測因子－相關性和影響力

第 3 章 增值洞察

第4章全球尿路上皮癌診斷市場展望

  • 主要亮點
  • 市場規模分析及預測
  • 全球尿路上皮癌診斷市場（按產品）展望
  • 全球尿路上皮癌診斷市場前景（按測試）
  • 全球尿路上皮癌診斷市場前景（按最終用戶）

5. 全球尿路上皮癌診斷市場按地區展望

  • 主要亮點
  • 2019 年至 2024 年按地區分類的歷史市場規模分析
  • 2025 年至 2032 年各地區當前市場規模分析及預測
  • 按地區分析市場吸引力

6. 北美尿路上皮癌診斷市場展望

7. 歐洲尿路上皮癌診斷市場展望

第 8 章東亞尿路上皮癌診斷市場展望

9. 南亞和大洋洲尿路上皮癌診斷市場展望

10. 拉丁美洲尿路上皮癌診斷市場展望

第 11 章中東和非洲尿路上皮癌診斷市場展望

第12章 競爭格局

  • 2025 年市場佔有率分析
  • 市場結構
  • 公司簡介（詳情－概述、財務狀況、策略、最新發展）
    • Roche Holding
    • Illumina
    • IDL Biotech
    • Agilent Technologies
    • Olympus Corporation
    • Philips Healthcare
    • Abbott Molecular
    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific, Inc.（Qiagen NV）
    • Danaher Corporation（Cepheid）
    • GE Healthcare
    • Pacific Edge
    • Nonacus Limited
    • KDx Diagnostics Inc.
    • Sysmex Europe SE

第13章 附錄

簡介目錄
Product Code: PMRREP14128

Persistence Market Research has recently released a comprehensive report on the worldwide market for urothelial carcinoma diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global urothelial carcinoma diagnostics market from 2025 to 2032.

Key Insights:

  • Urothelial Carcinoma Diagnostics Market Size (2025E): US$ 1,844.8 Mn
  • Projected Market Value (2032F): US$ 3,831.3 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 10.9%

Urothelial Carcinoma Diagnostics Market - Report Scope:

Urothelial carcinoma, commonly referred to as bladder cancer, is a prevalent malignancy requiring early and accurate diagnostics for effective treatment and patient outcomes. The market for urothelial carcinoma diagnostics includes a range of diagnostic modalities such as urine cytology, biomarker testing, fluorescence in situ hybridization (FISH), cystoscopy, and imaging techniques. These diagnostics play a crucial role in disease detection, staging, and monitoring recurrence. Market growth is driven by advancements in diagnostic technologies, increasing bladder cancer incidence, and the growing adoption of non-invasive diagnostic approaches, improving patient convenience and early detection rates.

Market Growth Drivers:

The global urothelial carcinoma diagnostics market is propelled by several key factors, including the rising prevalence of bladder cancer, particularly among aging populations and individuals with high-risk factors such as smoking and exposure to industrial chemicals. The growing preference for non-invasive and minimally invasive diagnostic methods, such as urine-based biomarker tests, is also contributing to market expansion. Additionally, technological advancements in molecular diagnostics and artificial intelligence-driven imaging solutions are enhancing diagnostic accuracy and efficiency. The increasing integration of liquid biopsy and next-generation sequencing (NGS) further supports market growth by offering precise, personalized diagnostic insights for urothelial carcinoma patients.

Market Restraints:

Despite promising growth prospects, the urothelial carcinoma diagnostics market faces challenges related to high diagnostic costs, limited accessibility in low-income regions, and reimbursement constraints. Many advanced diagnostic tests, including biomarker-based assays and genetic testing, remain expensive, limiting their widespread adoption in cost-sensitive markets. Furthermore, the complexity of regulatory approvals for novel diagnostic techniques poses barriers to market entry and innovation. Addressing these challenges requires collaboration among diagnostic manufacturers, healthcare providers, and policymakers to enhance affordability, accessibility, and regulatory harmonization.

Market Opportunities:

The urothelial carcinoma diagnostics market presents significant growth opportunities driven by the increasing adoption of artificial intelligence and machine learning in diagnostic imaging, the expansion of precision medicine approaches, and the rising focus on early cancer detection programs. Advancements in digital pathology and AI-assisted diagnostic platforms enhance diagnostic efficiency and reduce the likelihood of false positives or negatives, improving patient outcomes. Additionally, the development of cost-effective, rapid point-of-care diagnostic solutions for urothelial carcinoma could drive market penetration in underserved regions. Partnerships between diagnostic companies and research institutions to advance biomarker discovery and validation also offer lucrative growth prospects in this evolving market.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the urothelial carcinoma diagnostics market globally?
  • Which diagnostic modalities are witnessing the highest adoption in urothelial carcinoma detection and management?
  • How are technological advancements influencing the competitive landscape of the urothelial carcinoma diagnostics market?
  • Who are the key players contributing to the urothelial carcinoma diagnostics market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global urothelial carcinoma diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global urothelial carcinoma diagnostics market, including Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, and Bio-Rad Laboratories, focus on technological innovation, strategic collaborations, and product development to gain a competitive edge. These companies invest heavily in R&D to develop novel biomarker assays, liquid biopsy solutions, and AI-driven imaging tools for early and accurate detection of urothelial carcinoma. Partnerships with academic institutions and clinical research organizations facilitate the advancement of precision oncology diagnostics. Additionally, efforts to improve accessibility and affordability through pricing strategies, reimbursement advocacy, and expansion into emerging markets further support market growth.

Key Companies Profiled:

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Qiagen N.V.
  • Agilent Technologies
  • Illumina, Inc.
  • Siemens Healthineers
  • BD (Becton, Dickinson and Company)
  • Hologic, Inc.

Urothelial Carcinoma Diagnostics Market Segmentation

By Product

  • Reagent and Kits
  • Instruments

By Test

  • Urinalysis Test
  • Molecular Diagnostic Test
  • Biomarker Test

Cell-Based Test

  • Imaging Test
  • Cystoscopy
  • Ureteroscopy

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Research and Academic Institutes
  • Clinical Research Organizations

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Urothelial Carcinoma Diagnostics Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Urothelial Carcinoma Diagnostics Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Urothelial Carcinoma Diagnostics Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Reagent and Kits
      • 4.3.3.2. Instruments
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Urothelial Carcinoma Diagnostics Market Outlook: Test
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Test, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
      • 4.4.3.1. Urinalysis Test
      • 4.4.3.2. Molecular Diagnostic Test
      • 4.4.3.3. Biomarker Test
        • 4.4.3.3.1. Immuno-Histochemical Assay Test
        • 4.4.3.3.2. In Situ Hybridization Test
        • 4.4.3.3.3. Biopsy
        • 4.4.3.3.4. Cell-Based Test
      • 4.4.3.4. Imaging Test
      • 4.4.3.5. Cystoscopy
      • 4.4.3.6. Ureteroscopy
    • 4.4.4. Market Attractiveness Analysis: Test
  • 4.5. Global Urothelial Carcinoma Diagnostics Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospitals
      • 4.5.3.2. Diagnostic Laboratories
      • 4.5.3.3. Research and Academic Institutes
      • 4.5.3.4. Clinical Research Organizations
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Urothelial Carcinoma Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Urothelial Carcinoma Diagnostics Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Test
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Reagent and Kits
    • 6.4.2. Instruments
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 6.5.1. Urinalysis Test
    • 6.5.2. Molecular Diagnostic Test
    • 6.5.3. Biomarker Test
      • 6.5.3.1. Immuno-Histochemical Assay Test
      • 6.5.3.2. In Situ Hybridization Test
      • 6.5.3.3. Biopsy
      • 6.5.3.4. Cell-Based Test
    • 6.5.4. Imaging Test
    • 6.5.5. Cystoscopy
    • 6.5.6. Ureteroscopy
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospitals
    • 6.6.2. Diagnostic Laboratories
    • 6.6.3. Research and Academic Institutes
    • 6.6.4. Clinical Research Organizations
  • 6.7. Market Attractiveness Analysis

7. Europe Urothelial Carcinoma Diagnostics Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Test
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Reagent and Kits
    • 7.4.2. Instruments
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 7.5.1. Urinalysis Test
    • 7.5.2. Molecular Diagnostic Test
    • 7.5.3. Biomarker Test
      • 7.5.3.1. Immuno-Histochemical Assay Test
      • 7.5.3.2. In Situ Hybridization Test
      • 7.5.3.3. Biopsy
      • 7.5.3.4. Cell-Based Test
    • 7.5.4. Imaging Test
    • 7.5.5. Cystoscopy
    • 7.5.6. Ureteroscopy
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Diagnostic Laboratories
    • 7.6.3. Research and Academic Institutes
    • 7.6.4. Clinical Research Organizations
  • 7.7. Market Attractiveness Analysis

8. East Asia Urothelial Carcinoma Diagnostics Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Test
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Reagent and Kits
    • 8.4.2. Instruments
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 8.5.1. Urinalysis Test
    • 8.5.2. Molecular Diagnostic Test
    • 8.5.3. Biomarker Test
      • 8.5.3.1. Immuno-Histochemical Assay Test
      • 8.5.3.2. In Situ Hybridization Test
      • 8.5.3.3. Biopsy
      • 8.5.3.4. Cell-Based Test
    • 8.5.4. Imaging Test
    • 8.5.5. Cystoscopy
    • 8.5.6. Ureteroscopy
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Diagnostic Laboratories
    • 8.6.3. Research and Academic Institutes
    • 8.6.4. Clinical Research Organizations
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Urothelial Carcinoma Diagnostics Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Test
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Reagent and Kits
    • 9.4.2. Instruments
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 9.5.1. Urinalysis Test
    • 9.5.2. Molecular Diagnostic Test
    • 9.5.3. Biomarker Test
      • 9.5.3.1. Immuno-Histochemical Assay Test
      • 9.5.3.2. In Situ Hybridization Test
      • 9.5.3.3. Biopsy
      • 9.5.3.4. Cell-Based Test
    • 9.5.4. Imaging Test
    • 9.5.5. Cystoscopy
    • 9.5.6. Ureteroscopy
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Diagnostic Laboratories
    • 9.6.3. Research and Academic Institutes
    • 9.6.4. Clinical Research Organizations
  • 9.7. Market Attractiveness Analysis

10. Latin America Urothelial Carcinoma Diagnostics Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Test
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Reagent and Kits
    • 10.4.2. Instruments
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 10.5.1. Urinalysis Test
    • 10.5.2. Molecular Diagnostic Test
    • 10.5.3. Biomarker Test
      • 10.5.3.1. Immuno-Histochemical Assay Test
      • 10.5.3.2. In Situ Hybridization Test
      • 10.5.3.3. Biopsy
      • 10.5.3.4. Cell-Based Test
    • 10.5.4. Imaging Test
    • 10.5.5. Cystoscopy
    • 10.5.6. Ureteroscopy
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Diagnostic Laboratories
    • 10.6.3. Research and Academic Institutes
    • 10.6.4. Clinical Research Organizations
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Urothelial Carcinoma Diagnostics Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Test
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Reagent and Kits
    • 11.4.2. Instruments
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 11.5.1. Urinalysis Test
    • 11.5.2. Molecular Diagnostic Test
    • 11.5.3. Biomarker Test
      • 11.5.3.1. Immuno-Histochemical Assay Test
      • 11.5.3.2. In Situ Hybridization Test
      • 11.5.3.3. Biopsy
      • 11.5.3.4. Cell-Based Test
    • 11.5.4. Imaging Test
    • 11.5.5. Cystoscopy
    • 11.5.6. Ureteroscopy
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Diagnostic Laboratories
    • 11.6.3. Research and Academic Institutes
    • 11.6.4. Clinical Research Organizations
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Roche Holding
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Illumina
    • 12.3.3. IDL Biotech
    • 12.3.4. Agilent Technologies
    • 12.3.5. Olympus Corporation
    • 12.3.6. Philips Healthcare
    • 12.3.7. Abbott Molecular
    • 12.3.8. Bio-Rad Laboratories, Inc.
    • 12.3.9. Thermo Fisher Scientific, Inc. (Qiagen N.V.)
    • 12.3.10. Danaher Corporation (Cepheid)
    • 12.3.11. GE Healthcare
    • 12.3.12. Pacific Edge
    • 12.3.13. Nonacus Limited
    • 12.3.14. KDx Diagnostics Inc.
    • 12.3.15. Sysmex Europe SE

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations